KORU Medical Systems Inc (KRMD) Q2 2024 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com10-10

Revenue: $8.4 million for Q2 2024, a 22% increase over Q2 2023. Domestic Core Revenue: $6.2 million, a 14% growth driven by higher consumable volumes. International Core Revenue: $1.6 million, a 46% ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474001502?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Hv4TZqhqo9yhoIno4pz3QA--~B/aD0xNTE7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/36d8b923d3d33a35fb3a8e1df7ae2a4b","is_english":true,"pubTime":"2024-10-10 05:19","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2474001502","market":"us","top_or_hot":-1,"title":"KORU Medical Systems Inc (KRMD) Q2 2024 Earnings Call Highlights: Record Revenue Growth and ...","media":"GuruFocus.com","content":"<div>\n<p>Revenue: $8.4 million for Q2 2024, a 22% increase over Q2 2023.\nDomestic Core Revenue: $6.2 million, a 14% growth driven by higher consumable volumes.\nInternational Core Revenue: $1.6 million, a 46% ...</p>\n\n<a href=\"https://finance.yahoo.com/news/koru-medical-systems-inc-krmd-211936903.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>KORU Medical Systems Inc (KRMD) Q2 2024 Earnings Call Highlights: Record Revenue Growth and ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKORU Medical Systems Inc (KRMD) Q2 2024 Earnings Call Highlights: Record Revenue Growth and ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-10 05:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/koru-medical-systems-inc-krmd-211936903.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Revenue: $8.4 million for Q2 2024, a 22% increase over Q2 2023.\nDomestic Core Revenue: $6.2 million, a 14% growth driven by higher consumable volumes.\nInternational Core Revenue: $1.6 million, a 46% ...</p>\n\n<a href=\"https://finance.yahoo.com/news/koru-medical-systems-inc-krmd-211936903.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRMD","symbol_name":"Repro Med Systems, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/koru-medical-systems-inc-krmd-211936903.html","article_id":"2474001502","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Hv4TZqhqo9yhoIno4pz3QA--~B/aD0xNTE7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/36d8b923d3d33a35fb3a8e1df7ae2a4b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474001502","pubTimestamp":1728508776,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Revenue: $8.4 million for Q2 2024, a 22% increase over Q2 2023.Domestic Core Revenue: $6.2 million, a 14% growth driven by higher consumable volumes.International Core Revenue: $1.6 million, a 46% year-over-year growth.Novel Therapies Revenue: $600,000, a 50% improvement compared to the prior year.Gross Margin: 65%, an 890 basis point increase from the prior year.Cash Balance: $10.5 million as of June 30, 2024.2024 Revenue Guidance: Raised to $32 million to $32.5 million.2024 Gross Margin Guidance: Expected between 61% and 62%.Operating Expense: Approximately $23.5 to $24 million expected for 2024.GuruFocus has detected 4 Warning Signs with KRMD.For the complete transcript of the earnings call, please refer to the full earnings call transcript.KORU Medical Systems Inc  reported record revenues of $8.4 million for Q2 2024, marking a 22% growth over the same period in 2023.The company improved its gross margin to 65%, an 890 basis point increase compared to the prior year, due to manufac","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"KRMD":"Repro Med Systems, Inc.","KORU":"Direxion Daily South Korea Bull"},"translate_title":"KORU Medical Systems Inc(KRMD)2024年第二季度收益看涨期权亮点：创纪录的收入增长和……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KORU":1,"KRMD":1},"content_text":"Revenue: $8.4 million for Q2 2024, a 22% increase over Q2 2023.\nDomestic Core Revenue: $6.2 million, a 14% growth driven by higher consumable volumes.\nInternational Core Revenue: $1.6 million, a 46% year-over-year growth.\nNovel Therapies Revenue: $600,000, a 50% improvement compared to the prior year.\nGross Margin: 65%, an 890 basis point increase from the prior year.\nCash Balance: $10.5 million as of June 30, 2024.\n2024 Revenue Guidance: Raised to $32 million to $32.5 million.\n2024 Gross Margin Guidance: Expected between 61% and 62%.\nOperating Expense: Approximately $23.5 to $24 million expected for 2024.\n\n\nWarning! GuruFocus has detected 4 Warning Signs with KRMD.\n\nRelease Date: August 07, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nKORU Medical Systems Inc (NASDAQ:KRMD) reported record revenues of $8.4 million for Q2 2024, marking a 22% growth over the same period in 2023.\nThe company achieved a 46% year-over-year growth in its international core business, driven by improved IG supply and increased penetration in CIDP and SID approved indications.\nKORU Medical Systems Inc (NASDAQ:KRMD) received regulatory clearance for its FREEDOM EDGE infusion system in Japan, expanding its international reach.\nThe company improved its gross margin to 65%, an 890 basis point increase compared to the prior year, due to manufacturing efficiencies.\nKORU Medical Systems Inc (NASDAQ:KRMD) raised its 2024 full-year revenue and gross margin guidance, reflecting confidence in continued growth and operational improvements.\n\n Negative Points \n\nThe company anticipates more pressure on margins due to expanding into lower SP lesions and ongoing inflationary pressures in the supply chain.\nKORU Medical Systems Inc (NASDAQ:KRMD) expects higher cash usage in the second half of the year, driven by capital investments and R&D project spending.\nThe company noted a $300,000 accelerated shipment in Q2 that is not expected to recur, potentially impacting future revenue growth.\nThere is uncertainty regarding the impact of the expanded label for SCIG therapy, as it depends on healthcare practitioner adoption.\nKORU Medical Systems Inc (NASDAQ:KRMD) faces challenges in timing novel therapies revenues, which can be delayed due to collaboration complexities.\n\n Q & A Highlights \nQ: What is the current status of prefilled syringe penetration, and how is the 50 ml prefilled syringe launch progressing? A: Linda Tharby, President and CEO, explained that the market uptake for prefilled syringes is strengthening, with CSL's entire prefilled syringe platform now compatible with KORU's devices. The transition from vials to prefilled syringes is expected to bring more patients into the category due to its ease of use.\nQ: Do you plan to pursue TV2 clearance in other geographies beyond Japan? A: Linda Tharby confirmed that KORU is cleared for Cube true usage in the US and internationally. The Japan clearance is significant as it covers 95% of the Japanese market. KORU plans to seek further approvals in Latin America and Asia-Pacific regions.\nQ: How will the expanded label for Simplify, allowing direct SCIG therapy, impact your business? A: Linda Tharby noted that the expanded label for Simplify allows healthcare providers to start patients directly on SCIG therapy, which was previously off-label. This change is expected to simplify the process and potentially increase SCIG adoption.\nQ: What is the strategy for entering the Japanese market following the recent approval? A: Linda Tharby stated that KORU is setting up distributor and pharmaceutical company programs in Japan. The focus will initially be on consumables, as the market is largely electronic pump-based. Significant revenue contributions are expected in 2025.\nQ: Can you provide more details on the collaboration with SCHOTT Pharma? A: Linda Tharby highlighted that SCHOTT is the world's largest prefilled device manufacturer. The collaboration will focus on using KORU's Freedom system with SCHOTT's prefilled syringes, aiming to enhance convenience and infusion time. Commercial potential will be clearer in 2025.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474001502"}